Na Cocer Peptides rayt 
am 15 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Ovaviu fɔ di tin dɛn we dɛn dɔn lan
Mazdutide na wan nyu dכg we de akt lεk dual agonist fכ di glukagon lεk pεptida-1 (GLP-1) εn glukagon rεsεpכta dεm. di GLP-1 εn glukagon rεsεpכta dεm de ple imכtant rol dεm fכ mεtabolik rεguleshכn insay di mכtalman bכdi. GLP-1 na di L sεl dεm we de na di intestin de kכmכt fכs, i de kכmכt afta it, εn i de mek insulin sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn we i de inhibit glukagon sekreshכn, we de mek di blכd glukכs lεvεl dכn. GLP-1 de slo bak di gastric ɛmti, i de mek yu satisfay, ɛn i de ridyus di it we yu de it, we de ɛp fɔ mek yu gɛt wet. di glukagon risεptor dεm fכs de rεgεl di bכdi glukכs bεlε. afta glukagon tay to in risεptor, i de aktibכt wan siriכs signal transdyushכn path fכ promuot glycogenolysis εn gluconeogenesis, we de mek di bכdi glukכs lεvεl go כp. Mazdutide, as dual agonist, de ajɔst mεtabolik rεguleshכn tru wan kleva sinagεstik mεkanism.
Mekanism fɔ Akshɔn
Blɔd Glukɔs Rigyuleshɔn Mɛkanism
Promot insulin Sekreshכn: afta i biεn di GLP-1 rεsεpכta, Mazdutide de aktibכt dכwnstrim signal path dεm, inklud di cAMP-PKA signal path. aktibכshכn fכ dis path de εnhans di sεnsitiviti fכ pankrεas β-sεl dεm to glukכs, we de lid to upregulashכn fכ insulin jin εksprεshכn εn inkrεs insulin sεntesis εn sekreshכn. We di glukɔs na di blɔd go ɔp, Mazdutide kin mek di insulin kɔmɔt fayn fayn wan, ɛn dis kin mek di glukɔs na di blɔd go dɔŋ. pan di sik pipul dεm we gεt tayp 2 dayabεtis, Mazdutide de inkrεs di insulin sekreshכn afta dεn it tru dis mεkanism, we de εp fכ mεnten di blכd glukכs lεvεl stebul.
inhibishכn fכ glukagon sekreshכn: di akshכn we mazdutide de du pan glukagon rεsεpכta dεm de infכlכw glukagon sekreshכn bak. bay we i de biεn di glukagon rεsεpכta dεm, i de inhεbit signal transdyushכn insay pankrεas α sεl dεm, we de ridyus glukagon sεntesis εn rilis. dis de inhεbit glycogenolysis εn gluconeogenesis, we de ridyus di glukכs prodakshכn na di sכs εn i de εp mכr fכ lכs di blכd glukכs lεvεl. dis tu rεguleshכn fכ insulin εn glukagon sekreshכn de gi Mazdutide wan sכm advantej fכ blכd glukכs rεguleshכn, we de mek i ebul fכ kכntrכl mכr prεsis fכ di blכd glukכs lεvεl εn avכyd big fכlt.
Pasεnt chenj frכm di beslayn in bכdi wet ova tεm. Prכpכshכn כf patisipan dεm we rich di wεyt lכs tכgεt.
Weit manejmɛnt mɛkanism
apεtit rεgulεshכn: Mazdutide de biεn GLP-1 rεsεpכta dεm, we de aktibכt nyuron dεm na di haypothalamic apεtit rεguleshכn sεnta. dis nyuron dεm de tek pat pan di transmishכn fכ di satiety signal dεm, εn di akshכn we Mazdutide de du de εnhans dεn signal dεm ya, we de mek di it dεm we dεn de it dכn. i kin infכlכw bak di sekreshכn fכ di gεstrointestinal כmon dεm lεk ghrelin, we de rεgul di apεtit mכr. Insay klinik trial, di wan dɛn we tek pat we yuz Mazdutide bin ripɔt se dɛn nɔ bin want fɔ it ɛn dɛn nɔ bin de it bɛtɛ tin fɔ it ɛvride, ɛn dis bin mek dɛn lɔs dɛn wet.
di εnεji we yu de spɛn bכku bכku wan: Mazdutide kin mek yu lכs di wet bak bay we i de infכlכ di bכdi in εnεji mεtabolism. rεsכch sho se i kin mek di brawn adipos tisu aktibכt, we de mek in tεmכjεnik aktiviti bכku. di brawn adipos tisu rich wit maytochכndria εn i kin kכnsכm εnεji tru nכn-shivεr tεmכjεnεsis. mazdutide kin rεgεl di rilayt signal path dεm fכ promuot di difrεns εn aktibכshכn fכ brawn adiposyt dεm, we de εnhans dεn tεmכjεnik kapasiti, we de mek di bכdi in εnεji εkspεndεshכn εn achy fכ lכs weit. Mazdutide kin infכlכw bak di mεtabolism fכ di wayt adipos tisu, we de protεkt di kכnvכshכn fכ wayt fεt to brawn fεt, fכs optimiz fεt mεtabolism εn ridyus fεt akyumyuleshכn.
Yurik asid rεguleshכn mεkanism
Jin εksprεshכn rεguleshכn: Insay stכdi dεm we yuz wan rat mכdel fכ haypayurisεmia, dεn bin obsεv sכm chenj dεm na di εksprεshכn fכ sכm ki jin dεm fכlכ Mazdutide intavεnshכn. dis chenj dεm na di jin εksprεshכn kin achy ridכkshכn pan di yurik asid lεvεl bay we i de rεgεl di prεkursכr dεm fכ yurik asid sεntez εn tek pat pan prכsεs dεm lεk glycolipid mεtabolism εn purine mεtabolism. כprεgulεt jin dεm de protεkt yurik asid εkskrεshכn כ tek pat pan mεtabolik path dεm we de inhεbit yurik asid sεntez, we dכwnrεgulεt jin dεm de ridyus di sεntesis fכ prεkursכr fכ yurik asid sεntez, we de kכmprεhεnsiv lכs di sεrum yurik asid lεvεl.
mεtabolik path rεguleshכn: Analysis fכ rεnal transkriptכmiks sho se Mazdutide intavεnshכn sכmtεm εnrich KEGG path dεm we inklud bayl sekreshכn, di renin-angiotensin sistεm, histidine mεtabolism, platina rεsistεns, hεmatopoiεtik sεl laynej dεm, kompliment, εn di kכaguleshכn kaskad. rεguleshכn fכ dεn path dεm ya kin infכmeshכn indaykt wan fכ di yurik asid mεtabolism. di rεguleshכn fכ di bayl sekreshכn path kin afekt di bayl asid mεtabolism, we kכlכsכl rilayt to di lipid mεtabolism. di chenj dεm na di lipid mεtabolism kin in tכn afekt yurik asid prodakshכn εn εkskrεshכn. rεgulεshכn fכ di rεnin-angiotensin sistεm kin afekt di rεnal hεmodaynamiks εn tכbul fכnshכn, we de infכlכ di yurik asid riabsכpshכn εn εkskrεshכn.
Di we aw i de wok fayn
Glukɔs Kɔntrol Ifɛkt
Insay wan randomized, double-blind, placebo-controlled Phase 2 klinik trial in pasɛnt dɛn we gɛt tayp 2 dayabitis, Mazdutide sho signifyant blɔd glukɔs kɔntrol ifɛkt dɛn. Di stɔdi bin randomly asaynd big pipul dɛn we gɛt tayp 2 dayabitis fɔ gɛt 3 mg, 4.5 mg, ɔ 6 mg Mazdutide, 1.5 mg opin-lɛbul dulaglutide, ɔ plasɛbo, ɛn dɛn gi dɛn injɛkshɔn ɔnda di bɔdi fɔ 20 wik. Rizult sho se frɔm beslayn to wik 20, di min chenj na ɛmoglobin A1c (HbA1c) na di Mazdutide grup dɛn bin de frɔm -1.41% to -1.67%, we di dulaglutide grup bin gɛt chenj we na -1.35% ɛn di plasɛbo grup bin gɛt chenj we na 0.03%. Kכmpεr wit di plasεbo grup, di chenj dεm na di HbA1c lεvεl in כl di Mazdutide doz grup dεm bin stεdi sכmtin (ol P < 0.0001). Dis sho se Mazdutide na signifyant mɔ ifɛktiv pas plasɛbo fɔ lɔs HbA1c lɛvɛl pan pasɛnt dɛn we gɛt tayp 2 dayabitis, ɛn i kɔmparabl ɔ ivin bɛtɛ pas dulaglutide. di ridכkshכn pan di HbA1c lεvεl dεm de rεflek di Mazdutide in abiliti fכ ifektivli impruv lכng tεm glycemic kכntrכl in pasεnshכn, we de ridyus di insidεns fכ dayabεtik krכnik komplikεshכn dεm.
Di ifɛkt dɛn we pɔsin kin gɛt we i de lɔs yu wet
Mazdutide de sho se i gɛt impɔtant ɛfifikɛshɔn pan wet mɛnejɛmɛnt. Insay stɔdi dɛn we dɛn bin de tɔch big pipul dɛn we gɛt bɔku bɔku bɔdi ɔ we fat pasmak, 24 wiks we dɛn tek Mazdutide tritmɛnt sho gud ifɛkt fɔ lɛ dɛn lɔs dɛn wet. Ɔvaweit big pipul dɛn (bɔdi mas indeks [BMI] ≥24 kg/m²) wit polyphagia ɛn/ɔ at le wan ɔbisiti-rilayt kɔmɔrɔbiditi, ɔ fat big pipul dɛn (BMI ≥28 kg/m²), dɛn bin asaynd dɛn randomly (3:1:3:1:3:1) fɔ gɛt Mazdutide 3mg, 4.5mg, 6mg, ɛvri wik, ɛvri wik. ɔ mach plasɛbo tritmɛnt. Rizult sho se frɔm beslayn to wik 24, di min pasɛnt chenj na di wet na -6.7% (standad mistek 0.7) na di Mazdutide 3 mg grup, -10.4% (0.7) na di 4.5 mg grup, -11.3% (0.7) na di 6 mg grup, ɛn 1.0% (0.7) na di plesibo grup. We yu kɔmpia am wit plasɛbo, di tritmɛnt difrɛns fɔ Mazdutide akɔs ɔl di doz grup dɛn bin de frɔm -7.7% to -12.3% (ɔl P < 0.0001). Dis sho se Mazdutide kin ridyus di bɔdi wet bad bad wan pan big pipul dɛn we gɛt bɔku bɔku bɔdi ɔ we fat pasmak pan we we dipen pan di doz. Dis wet we pɔsin kin lɔs nɔ kin jɔs ɛp fɔ mek di sikman dɛn bɔdi fayn bɔt di tin we impɔtant pas ɔl na dat i kin mek i nɔ gɛt difrɛn sik dɛn we gɛt fɔ du wit fɔ fat, lɛk di sik dɛn we dɛn kin gɛt wit dɛn at ɛn di blɔd ɛn dayabitis.
Yurik asid-lɔr ɛfɛkt
In wan rat mכdel fכ haypayurisεmia, Mazdutide sho gud yurik asid-lכwεshכn ifekt dεm. Hyperuricemia wεn indyuz in rat bay כral administreshכn כf adenine εn potashכm כksinik asid, fכlכw tritmεnt wit difrεnt dos כf Mazdutide. di risalts sho se di mεdiכm- εn hεy-dos grup dεm fכ Mazdutide (0.05 mg/kg εn 0.075 mg/kg, we dεn administret via sכbkutan injεkshכn εvri 3 de) sכmtεm ridyus di sεrum yurik asid (SUA) lεvεl insay rat. Mazdutide bin impruv di kidni fכnshכn bak, ridyus di sεrum kriaytinin (SCr) εn urine protin (U-Pro) lεvεl, εn impruv di rεnal tisu patכlayzm. dis sho se Mazdutide nכ de כnli ridyus di sεrum yurik asid lεvεl bכt i gεt prכtektiv ifekt εgεst di kidni dεm we dεn dכn pwεl we haypayurisεmia de kכz.
Di say dɛn we yu fɔ yuz am
Tritmɛnt fɔ Tayp 2 Dayabitis
Given Mazdutide in signifyant efficacy in blood glucose control, e hol big potenshal for aplikeshon in di tritment of tayp 2 dayabitis. Naw, di tritmɛnt fɔ tayp 2 dayabitis de dipen mɔ pan di kɔmbaynshɔn fɔ bɔku mɛrɛsin fɔ kɔntrol di glukɔs lɛvɛl na di blɔd ɛn fɔ mek kɔmplikeshɔn nɔ apin. as nכvel dual risεptor agonist, Mazdutide in yכnik mεkanism fכ akshכn de mek i ebul fכ rεgεl glukכs mεtabolism na mכltipכl lεvεl dεm, we de gi nyu tritmεnt opshכn fכ pasεn dεm wit tayp 2 dayabεtis. We yu kɔmpia am wit tradishɔnal antidiabetic drɔgs, Mazdutide nɔ jɔs de mek di blɔd glukɔs lɛvɛl fayn fayn wan bɔt i de gi di bɛnifit fɔ ridyus di wet, we impɔtant mɔ fɔ bɔku pan di tayp 2 dayabitis pasɛnt dɛn we gɛt bɔku bɔku bɔdi ɔ we fat pasmak.
Fɔ fat ɛn fɔ kɔntrol pɔsin we gɛt bɔku bɔku bɔdi
Fɔ fat ɛn fɔ fat pasmak dɔn bi pɔblik wɛlbɔdi biznɛs na di wɔl we gɛt fɔ du wit di biginin fɔ difrɛn sik dɛn we nɔ de mɛn. Di impɔtant ifɛkt dɛm we Mazdutide gɛt pan wet mɛnejɛmɛnt de mek am wan pɔtɛnɛshɛl tritmɛnt opshɔn fɔ pipul dɛm we fat ɛn we gɛt bɔku bɔku bɔdi. We Mazdutide de rigul di apɛtit ɛn i de spɛn mɔ ɛnaji, i kin ɛp di wan dɛn we fat ɛn we gɛt bɔku bɔku bɔdi fɔ lɔs dɛn wet ɛn mek dɛn mɛtabolik stetɔs bɛtɛ. We yu kɔmpia am wit tradishɔnal we fɔ lɔs wet lɛk fɔ it ɛn ɛksesaiz, Mazdutide de gi yu wan mɔ ifɛktiv adjɔnt tritmɛnt opshɔn, mɔ fɔ di wan dɛn we de strɛs fɔ rich dɛn ideal wet tru layf stayl intavɛnshɔn. apat frכm dat, biכs fכ in mεkanism fכ akshכn we involv mכltipכl fysiolojikal rεgεdyushכn prכsεs dεm, Mazdutide kin gεt fayn ifekt pan di kכdivaskyul εn mεtabolik sistεm dεm we i de ridyus di wet, we de lכs di risk fכ kכmplikεshכn dεm we rilayt fכ fat.
Dɔn
fכ sכmari, as nכvel dual agonist fכ GLP-1 εn glukagon rεsεpכta dεm, Mazdutide de sho yunik mεkanism dεm fכ akshכn εn signifyant efikכs in bכdi glukכs rεguleshכn, wet mεnejmεnt, εn pכtεnshal yurik asid rεgulεshכn, we de ple wan imכtant rol fכ mεnejmεnt fכ tayp 2 dayabεtis, fεt, εn כvaweit kכndishכn dεm.
Sos dɛn we dɛn pul
[1] Zhang B, Cheng Z, Chen J, ɛn ɔda pipul dɛn. Efficacy ɛn Sefty fɔ Mazdutide in Chaynish Patient dɛn wit Tayp 2 Dayabitis: Wan Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial[J]. Dayabitis Keya, 2024,47(1):160-168.DOI:10.2337/dc23-1287.
[2] Nalisa D. L., Kuboia N, Dyab E, ɛn ɔda pipul dɛn. Efikεsi εn sef fכ Mazdutide pan wεyt lכs bitwin dayabεtik εn nכn-dayabεtik pasεnshכn dεm: wan sεstεmatik rivyu εn mεta-analysis כf randomizεd kכntrold trayal dεm[J]. Frontiers in Ɛndokrinɔlɔji, 2024,15. https://api.semanticscholar.org/CorpusID:267984513, di wan dɛn we de stɔdi bɔt di Baybul
[3] Ji L, Jiang H, Cheng Z, ɛn ɔda pipul dɛn. A phase 2 randomized controlled trial of mazdutide in Chaynish ɔvaweit big pipul ɔ big pipul dɛn we gɛt fat[J]. Nature Komyunikeshɔn, 2023,14(1):8289.DOI:10.1038/s41467-023-44067-4.
[4] Jiang H, Zhang Y, REN Y S. 77-LB: Wan nyu Glukagon-Lεk Pεptid-1 (GLP-1R) εn Glukagon (GCGR) Risεptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats[J]. Dayabitis, 2023. https://api.semanticscholar.org/CorpusID:259452040. Di wan dɛn we de stɔdi bɔt dis sik
Prodak we de fɔ yuz fɔ risach nɔmɔ:
